Sunday - July 5, 2026

Tipoffs for Maine (New England)

4 items
BLS Issues Report on Boston Area Employment - April 2022
BOSTON, Massachusetts, June 3 (TNSRep) -- The U.S. Department of Labor's Bureau of Labor Statistics - New England Regional Information Office issued the following report on June 2, 2022, entitled "Boston Area Employment - April 2022": Total nonfarm employment for the Boston-Cambridge-Nashua, MA-NH, metropolitan area increased by 132,100 over the year in April, the U.S. Bureau of Labor Statistics reported today. (See chart 1 and table 1.) Regional Commissioner William J. Sibley noted that the lo  more
Boston College: Fighting Global Cyber Crime
CHESTNUT HILL, Massachusetts, June 4 (TNSpol) -- Boston College issued the following news on June 3, 2022: * * * FBI Director Christopher Wray outlines threats and deterrence efforts at the sixth annual Boston Conference on Cyber Security, organized by Boston College and the FBI * * * Cyber threats from across the world⁠--from Russian attempts to influence the war in Ukraine by threatening cyberattacks against the West, to China stealing defense and industrial secrets, to Iran's 2021 targe  more
EPA Highlights Over $4 Million Brownfields Investment in Waterbury
WATERBURY, Connecticut, June 2 -- The Environmental Protection Agency issued the following news release on June 2, 2022: The U.S. Environmental Protection Agency's (EPA) Deputy Administrator Janet McCabe and EPA New England Regional Administrator David Cash, along with Senator Blumenthal, Senator Murphy, Congresswoman DeLauro, Connecticut Department of Energy and Environmental Protection (CT DEEP) Commissioner Katie Dykes, Waterbury Mayor Neil O'Leary and Naugatuck Valley Council of Governments  more
University of Texas's MD Anderson Cancer Center: Ibrutinib With Chemoimmunotherapy Improved Progression-Free Survival for Newly Diagnosed Mantle Cell Lymphoma Patients
HOUSTON, Texas, June 4 (TNSjou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on June 3, 2022: * * * MD Anderson-led trial is first to study BTK inhibitor as front-line option for MCL * * * Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) in patients 65 and over, researchers fr  more